What is the other name for Sitagliptin (DPP-4 inhibitor) Phosphate 100 MG Tablet?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Brand Name for Sitagliptin Phosphate 100 MG Tablet

Sitagliptin phosphate 100 mg tablet is marketed under the brand name Januvia.

Alternative Names and Classification

  • Generic name: Sitagliptin phosphate 1
  • Brand name: Januvia 2, 3
  • Other international brand names: Glactiv, Tesavel 4
  • Drug class: DPP-4 inhibitor (dipeptidyl peptidase-4 inhibitor) 1

Key Medication Information

Standard Dosing

  • Standard dose: 100 mg once daily for patients with normal renal function (eGFR >50 mL/min/1.73 m²) 5, 2
  • Moderate renal impairment (eGFR 30-50 mL/min/1.73 m²): 50 mg daily 5
  • Severe renal impairment (eGFR <30 mL/min/1.73 m²): 25 mg daily 5, 2

Clinical Use

  • Approved indications: Used as monotherapy or in combination with metformin, thiazolidinediones, sulfonylureas, or insulin for type 2 diabetes management 2, 4
  • Administration: Once daily dosing without need for titration or home blood glucose monitoring 3
  • Mechanism: Inhibits DPP-4 enzyme, increasing incretin hormone levels (GLP-1), which stimulates insulin secretion and inhibits glucagon production in a glucose-dependent manner 2, 6

Important Safety Considerations

  • Hypoglycemia risk: Low when used alone, but increases approximately 50% when combined with sulfonylureas 7
  • Weight effect: Weight-neutral 7, 4
  • Cardiovascular safety: Neutral effect on cardiovascular outcomes (TECOS trial) 7
  • Renal monitoring: Requires assessment of renal function before initiation and periodically thereafter to adjust dosing 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Sitagliptin Safety in Renal Impairment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Sitagliptin: an oral agent for glucose control.

Expert review of endocrinology & metabolism, 2008

Guideline

DPP-4 Inhibitors in Mealtime Insulin Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.